DOI:
10.1055/s-00000125
Senologie - Zeitschrift für Mammadiagnostik und -therapie
LinksClose Window
References
Welslau M, Dieras V, Sohn JH. et al.
Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer.
Cancer 2014;
120: 642-651
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.